ImmuPharma completes patient recruitment in Lupuzor trial

Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been completed, on target, within the its pivotal Phase III clinical trial of Lupuzor.

The AIM-traded firm described Lupuzor as its lead programme for the potential breakthrough compound for Lupus, the life threatening autoimmune disease.

“This is a major milestone for ImmuPharma confirming the completion of patient recruitment into this study,” said chairman Tim McCarthy.

“We look forward to providing further updates as and when possible on this pivotal Phase III trial as it progresses through 2017.”